Hussman Strategic Advisors Inc. purchased a new stake in shares of DaVita Inc. (NYSE:DVA – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 8,400 shares of the company’s stock, valued at approximately $1,116,000.
Several other hedge funds also recently added to or reduced their stakes in DVA. Hantz Financial Services Inc. increased its stake in DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in shares of DaVita during the 2nd quarter worth $36,000. Canada Pension Plan Investment Board acquired a new stake in shares of DaVita during the 2nd quarter worth about $43,000. Ameritas Advisory Services LLC purchased a new stake in DaVita in the 2nd quarter valued at about $47,000. Finally, Employees Retirement System of Texas acquired a new position in DaVita in the second quarter valued at about $49,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.
DaVita Stock Up 0.2%
DaVita stock opened at $105.86 on Thursday. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $179.60. The firm has a market cap of $7.47 billion, a PE ratio of 10.90, a price-to-earnings-growth ratio of 0.65 and a beta of 0.99. The company’s 50 day moving average is $113.97 and its two-hundred day moving average is $125.67.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on DVA shares. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Truist Financial dropped their target price on shares of DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a report on Monday, January 5th. Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. UBS Group restated a “buy” rating on shares of DaVita in a research report on Monday, December 15th. Finally, Zacks Research raised DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, DaVita currently has a consensus rating of “Hold” and a consensus price target of $145.60.
View Our Latest Stock Analysis on DaVita
DaVita Company Profile
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Featured Stories
- Five stocks we like better than DaVita
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
